Health
Designer DNA therapies shown to effectively target cancer stem cells – The Science Board
Using an engineered DNA therapeutic agent to silence transcription factor genes reduced myeloma stem cell abundance and increased the survival of mice bearing human…
Multiple myeloma is the second most common blood cancer in the U.S. It generally recurs and is refractory (reoccurs and is unresponsive to treatments). Despite novel therapies, treatment toxicities continue to be a challenge for patients and clinicians.
In multiple myeloma, proinflammatory cytokines and antiviral interferons derived from bone marrow play a key role in disease progression, including activation of interleukin 6 (IL-6) with downstream interferon-response factor (IRF) signaling.
IRF4…
-
Noosa News21 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General17 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News17 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
General23 hours ago‘We are here for you’: PM to bring help to flood zones